FIELD : medicine; pharmaceuticals.SUBSTANCE : invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. In formula (I), W is CH2; X is C; cycle A is phenyl or 5- or 6-member heteroaryl, wherein said heteroaryl contains 1, 2, 3 or 4 heteroatoms selected from N, O and S; m is integer from 0 to 2; each R1 is selected independently from (C1-C6) alkyl, optionally substituted with one or more halogen atoms, R2O, halogen, R5C(O)N(R6), R9S(O)2, R10S(O)2N(H), -O and R14R15NS(O)2; and when m is at least 2, two R1, attached to adjacent atoms of cycle A, can form, together with atoms to which they are attached, 5- or 6-member heterocycle or carbocycle; wherein heterocycle contains 1 or 2 heteroatoms selected from oxygen; each R2, R5, R6, R9, R10 and R14 is selected independently from H and (C1-C6) alkyl, wherein any alkyl is optionally substituted with one or more halogen atoms; R15 is selected from H, (C1-C6) alkyl, R16C (O) and R17OC(O); and each R16 and R17 is selected independently from H and (C1-C6) alkyl, where any alkyl is optionally substituted with one or more halogen atoms. Invention also relates to a pharmaceutical composition, to use of the compound, to a method of treating enteroviral infection. EFFECT : technical result : obtaining novel compounds of formula (I), having the properties of a phosphatidyl inositol-4-kinase IIIβ inhibitor.17 cl, 5 tbl, 32 ex